Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 95

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 95
---
 the 2,603,652     
 Preferred Shares issued and outstanding as of the date hereof, which will automatically convert upon the completion of this offering      
 at a 1:1 ratio; (ii) the issuance of 609,888 Ordinary Shares upon the automatic conversion of the $900,000 outstanding principal          
 of the 2020 CLAs, which will occur upon the completion of this offering; (iii) the issuance of 553,640 Ordinary Shares upon the automatic 
 conversion of the $450,000 outstanding principal of 2024 CLAs, which will occur upon the completion of this offering; (iv) the receipt    
 of an additional $100,000 under the Bridge Loan subsequent to December 31, 2024; (v) the receipt of a loan in the total amount of         
 $200,000 pursuant to the 2025 Loan Agreements; and (vi) the expiration of certain outstanding warrants to purchase up to 167,365          
 Ordinary Shares in March 2025.                                                                                                            |

| ● | on a                                                                                            
 pro forma as adjusted basis to give further effect to: (i) the sale of 1,000,000 Ordinary       
 Shares in this offering at an initial public offering price of $11.00 per Ordinary Share,       
 which is the midpoint of the price range set forth on the cover page of this prospectus,        
 after deducting underwriting discounts and commissions and estimated offering expenses payable  
 by us; (ii) repayment of the Bridge Loan in the total amount of $350,000 plus accrued interest  
 and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the loan        
 under the 2024 Loan Agreements in the total amount of $150,000 plus accrued interest and        
 an aggregate risk premium in the amount of $50,000; (iv) the repayment of the loan under        
 the December 2024 Loan Agreement in the total amount of $117,000 plus VAT plus accrued interest 
 and an aggregate risk premium of approximately $35,100 plus VAT; (v) the repayment of the       
 loan under the 2025 Loan Agreements in the total amount of $200,000 plus accrued interest       
 and an aggregate risk premium in the amount of $100,000; and (vi) total payment of $430,000 to  
 CSL in connection with the CSL Settlement.                                                      |

The pro forma as adjusted
information set forth in the table below is illustrative only and will be adjusted based